Italy Generics Market Summary, Competitive Analysis and Forecast to 2027

Key Highlights

• For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. The market value is evaluated at ex-factory prices.
• The Italian generics market had total revenues of $1.3 billion in 2022, representing a compound annual growth rate (CAGR) of 1.5% between 2017 and 2022.
• Market consumption volume increased with a CAGR of 2.1% between 2017 and 2022, to reach a total of 23.9 % in 2022.
• According to in-house research, the consumer price inflation-health was 0.9% in 2022. Italy had the least consumer price inflation-health, compared to other European countries, which justifies the slow growth in the market.

Scope

• Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Italy
• Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Italy
• Leading company profiles reveal details of key generics market players’ global operations and financial performance
• Add weight to presentations and pitches by understanding the future growth prospects of the Italy generics market with five year forecasts

Reasons to Buy

• What was the size of the Italy generics market by value in 2022?
• What will be the size of the Italy generics market in 2027?
• What factors are affecting the strength of competition in the Italy generics market?
• How has the market performed over the last five years?
• What are the main segments that make up Italy's generics market?